We are live on ! Find out more
AVTX icon

Avalo Therapeutics
AVTX

29 hedge funds and large institutions have $63.2M invested in Avalo Therapeutics in 2024 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

557% more capital invested

Capital invested by funds: $9.62M → $63.2M (+$53.6M)

400% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 2

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

38% more funds holding

Funds holding: 21 → 29 (+8)

6.24% less ownership

Funds ownership: 74.86% → 68.63% (-6.2%)

Holders
29
Holders Change
+8
Holders Change %
+38.1%
% of All Funds
0.42%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
10
Increased
3
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BI
BVF Inc
California
+$9.97M
2
DTC
Deep Track Capital
Connecticut
+$9.97M
3
O
OrbiMed
New York
+$9.97M
4
RCM
RA Capital Management
Massachusetts
+$9.97M
5
IC
Ikarian Capital
Texas
+$9.44M

Top Sellers

Rank Fund Capital Flow
1
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$7K
2
BCV
Banque Cantonale Vaudoise
Switzerland
-$4K
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$10
Name Holding Trade Value Shares
Change 		Change in
Stake
IC
1
Ikarian Capital
Texas
$9.22M +$9.44M +915,629 +1,673%
DTC
2
Deep Track Capital
Connecticut
$9.19M +$9.97M +967,000 New
O
3
OrbiMed
New York
$9.19M +$9.97M +967,000 New
RCM
4
RA Capital Management
Massachusetts
$9.19M +$9.97M +967,000 New
BI
5
BVF Inc
California
$9.15M +$9.97M +967,000 New
LGM
6
Logos Global Management
California
$5.12M – – –
CC
7
Commodore Capital
New York
$4.59M +$4.57M +443,000 +1,108%
TCM
8
TCG Crossover Management
California
$4.59M +$4.98M +483,000 New
BFM
9
Boothbay Fund Management
New York
$1.56M +$1.69M +164,092 New
SCM
10
Sio Capital Management
New York
$679K – – –
AAA
11
Affinity Asset Advisors
New York
$426K – – –
Vanguard Group
12
Vanguard Group
Pennsylvania
$98.1K – – –
Geode Capital Management
13
Geode Capital Management
Massachusetts
$95.6K +$104K +10,111 New
UBS Group
14
UBS Group
Switzerland
$58.3K +$26.3K +2,551 +71%
Bank of America
15
Bank of America
North Carolina
$53.2K – – –
TRCT
16
Tower Research Capital (TRC)
New York
$3.57K +$3.88K +376 New
BlackRock
17
BlackRock
New York
$3.13K – – –
Morgan Stanley
18
Morgan Stanley
New York
$96 – – –
BNP Paribas Financial Markets
19
BNP Paribas Financial Markets
France
$38 – – –
Group One Trading
20
Group One Trading
Illinois
$19 – – –
JP Morgan Chase
21
JP Morgan Chase
New York
$19 – – –
Osaic Holdings
22
Osaic Holdings
Arizona
$19 – – –
AWM
23
Activest Wealth Management
Florida
$10 – – –
KFI
24
Key Financial Inc
Pennsylvania
$10 – – –
PA
25
Parallel Advisors
California
$10 – – –
1
2

AVTX Hedge Fund Activity: Q3 2024 in Review

29 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Avalo Therapeutics (AVTX) for Q3 2024, worth a combined $63.2M — up 557% from $9.62M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new AVTX positions and 2 closed out — a net gain of 8 holders — while 3 added to existing stakes and 1 trimmed.

The largest buyer was BVF Inc, opening a new position worth an estimated $9.97M. The largest seller was Royal Bank of Canada, exiting entirely with an estimated $7K sold.

  • 29 institutional investors held Avalo Therapeutics (AVTX) as of Q3 2024, up from 21 in Q2 2024.
  • Funds reported $63.2M of Avalo Therapeutics stock for Q3 2024, up 557% quarter-over-quarter.
  • 10 funds opened new Avalo Therapeutics positions in Q3 2024 and 2 closed out, a net change of +8 holders.
  • The largest Avalo Therapeutics buyer in Q3 2024 was BVF Inc, an estimated $9.97M added.
  • The largest Avalo Therapeutics seller in Q3 2024 was Royal Bank of Canada, an estimated $7K sold.

Based on aggregated 13F filings for Q3 2024.